Centro Cardiologico Monzino — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Centro Cardiologico Monzino appears in 26 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials26

Recruiting shown4

Roles2

SourceClinicalTrials.gov

Clinical trials

26 shown

The Effects of Body Scan on Enteroception in Patients With Heart FailureNCT06737679 · lead sponsor · 2025-01-28

Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution: Identification of Cardiovascular Risk in Patients with Heart FailureNCT06884631 · lead sponsor · 2021-02-10

Validation of the Italian SCHFI v.8 and the CC-SCHFI v.3NCT07608393 · lead sponsor · 2026-05-01

NOT_YET_RECRUITING

Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart FailureNCT05591443 · lead sponsor · 2023-05-01

A Dynamic Evaluation of Chronic Heart Failure Prognosis: the MECKI ScoreNCT06070519 · lead sponsor · 2023-05-01

Italian Digital Primary Cardiovascular Prevention StudyNCT05339841 · lead sponsor · 2022-06-10

ACTIVE_NOT_RECRUITING

Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart FailureNCT05770167 · lead sponsor · 2022-05-06

Coronary Artery Calcium and Cardiovascular Risk Factors Analysis After RT or Breast CancerNCT05775822 · lead sponsor · 2022-03-24

Cardiovascular Risk Assessment in a Cohort of Italian Patients With Type 1 Diabetes Mellitus (CARDT1)NCT06290544 · lead sponsor · 2021-11-29

Effect of the Use of Protective Masks on the Ability to Perform Daily Activities in Patients with Heart Failure or Obstructive Pulmonary DiseaseNCT05762406 · lead sponsor · 2021-06-16

Furosemide-induced Diuresis With Matched Dehydration Compared to Standard Diuretic Therapy in Patients With Acute Heart Failure and Overt Fluid OverloadNCT05807152 · lead sponsor · 2019-02-19

Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart FailureNCT04434170 · lead sponsor · 2018-10-15

NIRS and DO2i CorrelationNCT03281707 · lead sponsor · 2017-09-30

Surfactant Derived Protocol in Heart FailureNCT06896461 · lead sponsor · 2016-05-06

Indacaterol in Heart Failure Patients: Any Role on Lung Fluid RegulationNCT02598505 · lead sponsor · 2015-09-01

ProSALUTE: Community Program for Cardiovascular HealthNCT03129165 · lead sponsor · 2015-05-11

Dead Space Evaluation in Pulmonary HypertensionNCT02892981 · lead sponsor · 2015-01-01

Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)NCT02261948 · lead sponsor · 2012-09-01

Nebivolol Versus Bisoprolol Versus Carvedilol in Heart FailureNCT00517725 · lead sponsor · 2007-07-01

Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart FailureNCT00517426 · lead sponsor · 2007-07-01

Treatment of Severe Heart Failure by UltrafiltrationNCT00360958 · lead sponsor · 2006-08-01

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)NCT06311708 · collaborator · 2023-01-31

Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of ImagingNCT05081115 · collaborator · 2021-04-01

OPTImal PHARMacological Therapy for Patients With Heart Failure: The OPTIPHARM-HF RegistryNCT06192524 · collaborator · 2022-07-18

Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19NCT04624503 · collaborator · 2020-10-01

Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular FunctionNCT02509754 · collaborator · 2016-01-01

Drugs studied in this sponsor's trials

8 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Centro Cardiologico Monzino as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

placebo2

acetazolamide1

bisoprolol1

carvedilol1

indacaterol1

levosimendan1

nebivolol1

sacubitril / valsartan1

placebo RxCUI 8375 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials acetazolamide RxCUI 167 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bisoprolol RxCUI 19484 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial carvedilol RxCUI 20352 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial indacaterol RxCUI 1114326 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial levosimendan RxCUI 73107 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nebivolol RxCUI 31555 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sacubitril / valsartan RxCUI 1656339 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor21

collaborator5

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.